It’s good times for Biosite Inc. shareholders—and maybe, finally, for the diagnostics industry as a whole.
As IN VIVO goes to press, Inverness Medical Innovations Inc. is about to enter into discussions to buy Biosite for...
Inverness Medical Innovations and Beckman Coulter are currently in a bidding war for Biosite and its point of care BNP test. The fight is just one example of the demand for innovative diagnostic test content. The recent upswing in IVD deal-making, along with renewed VC interest in diagnostics, suggests that the area's potential to drive health care innovation by directing therapy more efficiently is finally being recognized.
It’s good times for Biosite Inc. shareholders—and maybe, finally, for the diagnostics industry as a whole.
As IN VIVO goes to press, Inverness Medical Innovations Inc. is about to enter into discussions to buy Biosite for...
MedTech Forum 2025 was less MDR-focused than in previous years, as macro issues and exogenous threats were forced further into the center of medtech business thinking.
In a conversation with In Vivo, CEO Jon Congleton discusses Mineralys’s data-rich journey toward an NDA filing, the significance of recent trial wins and how its candidate may offer a dual benefit in blood pressure and renal protection.
Qubit Pharmaceuticals and Sorbonne University launched a quantum AI model that could slash drug synthesis requirements and enable exploration of previously undruggable targets.